A series of benzothiazole bearing piperazino-arylsulfonamides (5a-k), and arylthiol analogues (6a-j) as well as substituted benzothiazoles having sulfonamides (9b, 9l-n and 10) have been synthesized. All compounds were evaluated, in vitro, for their antiproliferative activity against a large panel of human tumor-derived cell lines. Compounds 5c, 5d, 5j, 6b, 6c and 6j were the most potent analogues in this series, showing activity against both cell lines derived from haematological and solid tumors (CC 50 range = 8-24 µM), only 5d was found to be selective and not cytotoxic to normal human tissues.
Introduction
A number of benzothiadiazoles showed selective antiproliferative activity, especially the phenylsubstituted benzothiazoles, [1] [2] [3] while condensed pyrimido benzothiazoles and benzothiazolo quinazolines exert antiviral activity. 4 Substituted 2-(4-aminophenyl)benzothiazoles were developed and examined, in vitro, for their antiproliferative activity in ovarian, breast, renal and colon carcinoma human cell lines, [5] [6] [7] [8] imidazo benzothiazoles, 9, 10 as well as, polymerized benzothiazoles 11 and other substituted benzothiazoles 12 showed remarkable antitumor activity against malignant cell lines. The aryl amines, 2-(4-amino-3-methylphenyl)benzothiazole, 13 were deduced from comparison with compounds 5a-k. The CH 2 S protons resonated at δ 4.02-4.45 ppm as a singlet. In the 13 C NMR spectra of 6a-j, CH 2 S carbon appeared at the region δ 31.8-37.1 ppm. Resonances at δ 24.2, 15.7 and 33.5 pm were assigned to the CH 3 carbons of 6c, 6d and 6f, respectively. The higher-field resonances at the region δ 168.0-170.0 ppm were attributed to the carbonyl. The carbons of aromatic, pyridine, pyrimidine, thiazole, triazole, imidazole, tetrazole, benzoxazole, benzothiazole, and benzoimidazole conjugated to CH 2 S group were assigned.
In vitro antiproliferative activity
Compounds 5a-k, 6a-j, 9b, 9l-n and 10 were tested, in vitro, against a large panel of human cell lines derived from hematological [CD4 + human T-cells containing an integrated HTLV-1 For comparative purposes, we evaluated the cytotoxic activities of the compounds relative to Doxorubicin. As shown in Table 1 , the benchmark active compounds were 5c especially against the human prostate carcinoma (DU-145) cell lines (CC 50 = 8±3 µM) and 5d against the human hepatocellular carcinoma (HepG2) and human prostate (DU-145) cell lines (CC 50 = 8±2 µM, 9±2 µM, respectively).
Introduction of a chloro-, dichlorophenyl and dichlorothiophene residues in the backbones of 5c, 5d and 5j, generally enhanced the potency: dramatic changes in activity were observed with the other congeneres (compounds 5a,b, 5e-i, 5k). Thus, replacement of either (or both) of the chloro groups by hydrogen (5a), methyl (5b), nitro (5e), trifluromethyl (5f), or methoxy (5g) substituents had a deactivating effect. Similarly, the analogues 5h, 5i and 5k having congeneres other than chloro substituent showed only low micromolar inhibitory potency.
All of the piprazino-arylthio analogues (6a-j) were found to be markedly less active against the cancer cell lines tested when compared to the lead compound 5c, 5d and 5i, except 6c and 6j, which exhibited activity against both cell lines derived from haematological and solid tumors.
The metabolic biotransformation of 5b, 5c and 5d in human cells might be mediated through the CYP1 family of cytochrome P450s. 26 Compounds 9b, 9l-n and 10 were found to be inactive against all panels of tumor cell lines (CC 50 >100 µM), data not shown. 5f >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 5d and 5j) being the agents of choice for further pharmacological evaluation. Further experiments aimed at defining the target and the mechanisms of the inhibitory effect showed by these molecules are in progress and the results will be reported in a forthcoming paper.
Experimental Section
General Procedures. Melting points are uncorrected and were measured on a Büchi melting point apparatus B-545 (Büchi Labortechnik AG, Switzerland). Microanalytical data were obtained with a Vario, Elemental apparatus (Shimadzu, Japan). NMR spectra were recorded on 300 MHz ( 
General procedure for the preparation of N-(2-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)-2-oxoethyl)arylsulfonamides (5a-k)
A solution of 4 (1.00 mmol) and an arylsulfonyl chloride (a-k) (1.00 mmol) in CH 2 Cl 2 (50 mL) containing Et 3 N (0.1 mL, 1.00 mmol) was stirred at 23 °C for 20 h. The solvent was evaporated to dryness and the residue was purified on thin layer chromatography, using CHCl 3 -MeOH (30:1) as eluent to give the desired product, which recrystallized from EtOH. 
N-(2-(4-(Benzo[d]thiazol-2-yl)piperazin-1-yl)-2-oxo-ethyl)benzenesulfonamide (5a)
.
N-(2-(4-(Benzo[d]thiazol-2-yl)piperazin-1-yl)-2-oxo-ethyl)-4-nitrobenzenesulfonamide (5e).
From e (0.22 g). Yield: 0.44 g (96%); mp 182-185 °C. 
N-(2-(4-(Benzo[d]thiazol-2-yl)piperazin-1-yl)-2-oxo-ethyl)-2,5-dichlorothiophene-3-

sulfonamide (5j
N-(2-(4-(Benzo[d]thiazol-2-yl)piperazin-1-yl)-2-oxoethyl)-3-bromo-5-chlorothiophene-2-
sulfonamide (5k
General procedure for preparation of 1-(4-(benzothiazol-2-yl)piperazinyl-1-yl)-2-(arylthio)-ethanone (6a-j)
To a stirred solution of 4 (1.00 mmol) in DMF (10 mL) was added 60% NaH (1.0 mmol). After 15 min, the arylthiol (1.00 mmol) was added with stirring at 23 °C for 48 h. The solution was evaporated to dryness and the residue was extracted into CH 2 Cl 2 (3 x 15 mL) and the organic solution was washed with water (2 x 20 mL), dried with Na 2 SO 4 and concentrated under reduced pressure to obtain the product which purified using thin layer chromatography (CHCl 3 -MeOH). The products were recrystallized from EtOH. Benzo[d]thiazol-2-yl)piperazin-1-yl)-2-(pyridin-2-ylthio)ethanone (6b). From b (0.18  g) (1H-1,2,3-Triazol-5-ylthio)-1-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)ethanone (6e) . From e (0.17 g). Yield: 0.12 g (33%); mp 160-162 °C. Benzo[d]thiazol-2-yl)piperazin-1-yl)-2-(1-methyl-1H-imidazol-2-ylthio)ethanone (6f) . From f (0.18 g). Yield: 0.23 g (62%); mp 120-122 °C. Benzo[d]thiazol-2-yl)piperazin-1-yl)-2-(1-phenyl-1H-tetrazol-5-ylthio)ethanone (6g) . 
1-(4-(Benzo[d]thiazol-2-yl)piperazin-1-yl)-2-(phenylthio)ethanone (6a
1-(4-(
1-(4-(Benzo[d]thiazol-2-yl)piperazin-1-yl)-2-(4-methylpyrimidin-2-ylthio)ethanone(6c
2-
1-(4-(
Cytotoxicity assays
Cell cultures were seeded at 1x10 5 cells/ml in 96 multiwell plates in specific media supplemented with 10% FCS and antibiotics and incubated at 37 °C in a humidified CO 2 (5%) atmosphere in the absence or presence of serial dilutions of test compounds. Cell viability was determined after 96 hrs at 37 °C by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) method. 26 Compounds were dissolved in DMSO at 100 mM and then diluted into culture medium.
